{
    "clinical_study": {
        "@rank": "132703", 
        "arm_group": [
            {
                "arm_group_label": "Sevelamer HCl", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Calcium-based binder", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The study is designed to compare sevelamer vs. calcium-based phosphate binder in\n      hemodialysis patients to achieve full-scale of medical care, including reduction of\n      atherosclerotic risk factors, reduction of vascular access reconstruction rate, and\n      pharmacoeconomic analysis."
        }, 
        "brief_title": "Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis Patients", 
        "completion_date": {
            "#text": "June 2009", 
            "@type": "Actual"
        }, 
        "condition": [
            "Hemodialysis", 
            "Hyperphosphatemia", 
            "Cardiovascular Events"
        ], 
        "condition_browse": {
            "mesh_term": "Hyperphosphatemia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males or females aged between 18-70 years old\n\n          -  Subject with hyperphosphatemia (5.5 - 8.5 mg/dL) at both WK(-2) and WK0\n\n          -  On stable TIW hemodialysis for 3 months or longer\n\n        Exclusion Criteria:\n\n          -  Patients with hypercalcemia (corrected serum calcium > 10.5 mg/dL)\n\n          -  Any of the following abnormalities: ALT or AST > 3X ULN; iPTH > 1000 or < 150 pg/mL\n\n          -  History of dysphagia or swallowing disorders\n\n          -  History of GI motility disorder or GI bleeding within 3 months prior to entry"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "166", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01755078", 
            "org_study_id": "CPT-REN-002"
        }, 
        "intervention": [
            {
                "arm_group_label": "Sevelamer HCl", 
                "description": "Non-metal phosphate binder", 
                "intervention_name": "Sevelamer HCl", 
                "intervention_type": "Drug", 
                "other_name": "Renagel Tablets"
            }, 
            {
                "arm_group_label": "Calcium-based binder", 
                "intervention_name": "Calcium-based phosphate binder", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Calcium carbonate", 
                    "Calcium acetate"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Calcium, Dietary", 
                "Calcium Carbonate", 
                "Sevelamer", 
                "Calcium acetate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Phosphate binder", 
        "lastchanged_date": "December 20, 2012", 
        "number_of_arms": "2", 
        "official_title": "Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis Patients", 
        "overall_official": {
            "affiliation": "China Medical University Hospital", 
            "last_name": "Chiu-Ching Huang, Professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: State Administration of Traditional Chinese Medicine of the People's Republic of China", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Composite end-point of Ca, P, Ca*P within K/DOQI recommendation", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01755078"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline, Ca, P, Ca*P", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Change from baseline, lipid profile", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Change from baseline, CRP", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Change from baseline, iPTH (stragified)", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Change from baseline, homocysteine, folate and Vit B12", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "CV-related event rate (OPD admission and hospitalization)", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Comparison of medical-related expenses between group", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Chugai Pharma Taiwan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chugai Pharma Taiwan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2007", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}